Toronto-based Intellipharmaceutics International earned Food and Drug Administration approval for its levetiracetam extended-release tablets.
Here are four things to know.
1. Levetiracetam is intended to treat partial onset seizures related to epilepsy.
2. The tablets are a generic equivalent to UCB's brand name drug Keppra XR.
3. Sales of sales Keppra XR and all other generic equivalents already on the market in the U.S. reached about $168 million for the 12 months ended December 2015, according to Symphony Health Solutions.
4. Intellipharmaceutics has eight other new drug applications pending FDA review.
More articles on supply chain:
6 must-reads for supply chain leaders this week
UPS to offer Saturday ground delivery services
FDA approves new liquid drug for hypothyroidism